U.S. AI-Driven Diabetic Retinopathy Screening Companies, Market Entry and Expansion Strategies 2026

Top Vendors in the U.S. AI-Driven Diabetic Retinopathy Screening Market & Their Offerings

Company Offerings

Supply Chain Analysis

R&D

• Research and development for AI-driven diabetic retinopathy screening in the U.S. has shifted from retrospective research to real-world clinical use. Current efforts focus on improving early detection, integrating screening tools into primary care settings, and increasing patient follow-up rates to enhance treatment outcomes.
• Key players: Digital Diagnostics, Eyenuk, Google Health, and IBM Watson Health

Clinical Trials

• Clinical trials studies for AI-based diabetic retinopathy screening in the U.S. have evolved from validating diagnostic accuracy to proving effectiveness in real clinical environments. Current trials emphasize improving screening rates in underserved populations, primary care facilities, and pediatric settings to enhance early detection.
• Key players: Digital Diagnostics, Eyenuk, Google Health, and Medtronic.

Patient Support and Services 

• Patient support and service programs for AI-based diabetic retinopathy screening in the U.S. are designed to expand access to eye care, deliver faster screening results, and improve patient adherence to follow-up care. These initiatives also help reduce healthcare disparities by extending screening services to underserved communities.
• Key players: Topcon Healthcare, Canon Medical Systems, Optomed, and IDx Technologies.

Market Growth

The U.S. AI-driven diabetic retinopathy screening market size was estimated at USD 191.05 million in 2025 and is predicted to increase from USD 231.59 million in 2026 to approximately USD 1308.85 million by 2035, expanding at a CAGR of 21.22% from 2026 to 2035.

What are the Recent Developments in the U.S. AI-driven diabetic retinopathy screening market?

• In July 2025, AEYE Health formed a strategic partnership with Ford Medical to expand access to autonomous AI-based diabetic eye screening solutions. Through this collaboration, the companies aim to introduce automated diabetic retinopathy screening services across pharmacies and non-acute healthcare centers in the U.S., helping improve early disease detection and making retinal screening more accessible and efficient for patients.
• In July 2025, Topcon Healthcare acquired Intelligent Retinal Imaging Systems (IRIS) to strengthen its capabilities in AI-based retinal diagnostics. The acquisition supports Topcon’s “Healthcare from the Eye” initiative by enhancing clinical decision-making for diabetic retinopathy. The company plans to integrate IRIS technologies into its existing platforms to improve the accuracy and efficiency of retinal disease detection.

Know the this market deeper with a free sample including segment data and competitor analysis; Download Free Sample Now